Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Lung cancer

Deoxythymidylate kinase (DTYMK); serine/threonine kinase 11 (STK11; LKB1)

Cell culture studies suggest inhibiting DTYMK could help treat LKB1 mutant lung cancer. A small hairpin RNA screen in mouse cells derived from lung tumors showed that Dtymk deficiency was lethal in Lkb1 mutant cells. In a panel of LKB1 mutant lung cancer cell lines, DTYMK-targeting shRNA decreased growth compared with control shRNA. Next steps could include developing pharmacological inhibitors of DTYMK.

SciBX 6(26); doi:10.1038/scibx.2013.653
Published online July 11, 2013

Patent and licensing status unavailable

Liu, Y. et al. Cancer Discov.; published online May 28, 2013;
doi:10.1158/2159-8290.CD-13-0015
Contact: Kwok-Kin Wong, Dana-Farber Cancer Institute, Boston, Mass.
e-mail:
kwong1@partners.org